Logo 1.png
Aeterna Zentaris Announces Continued Expansion of Intellectual Property Portfolio for Macimorelin with Additional Patent Applications
July 31, 2020 07:35 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., July 31, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and...
Logo 1.png
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
July 29, 2020 07:05 ET | Aeterna Zentaris Inc
CHARLESTON, S.C., July 29, 2020 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company commercializing and...
logo.jpg
Biofrontera reports preliminary unaudited sales revenue for the first six months of 2020
July 14, 2020 06:08 ET | Biofrontera AG
Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutical...
logo.jpg
Biofrontera confirms financing need
June 30, 2020 08:30 ET | Biofrontera AG
Leverkusen, Germany, June 30, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirmed the...
logo.jpg
Biofrontera dismisses case against DUSA Pharmaceuticals, Inc. in California state court
May 13, 2020 04:00 ET | Biofrontera AG
Leverkusen, Germany, May 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or “Biofrontera”), an international biopharmaceutical company, today...
logo.jpg
Biofrontera Reports Full Year 2019 Financial Results
April 20, 2020 11:06 ET | Biofrontera AG
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its...
logo.jpg
Biofrontera AG enters into exclusive license agreement with Maruho Co., Ltd.
April 20, 2020 04:20 ET | Biofrontera AG
Leverkusen, Germany, April 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, has...
logo.jpg
Biofrontera announces conference call to be held on April 21, 2020 to discuss full year 2019 financial results
April 09, 2020 12:30 ET | Biofrontera AG
Leverkusen, Germany, April 09, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
April 06, 2020 09:00 ET | American BriVision Holding Corporation
PDC-1421, the active ingredient of ABV-1505, is being expanded into Adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) A site monitoring visit for the...
logo color s and clearside.jpg
Clearside Biomedical to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Corporate Update on Wednesday, March 11, 2020
February 27, 2020 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...